Cargando…

Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification

Vaccine hesitancy is a global health threat which may hinder the widespread acceptance of several COVID-19 vaccines. Following the collection of 2470 responses from an anonymous questionnaire distributed between October and November 2020 across Israel, we analyzed the responses of physicians, life s...

Descripción completa

Detalles Bibliográficos
Autores principales: Dror, Amiel A., Daoud, Amani, Morozov, Nicole G., Layous, Eli, Eisenbach, Netanel, Mizrachi, Matti, Rayan, Doaa, Bader, Ahmad, Francis, Shawky, Kaykov, Edward, Barhoum, Masad, Sela, Eyal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149582/
https://www.ncbi.nlm.nih.gov/pubmed/34037927
http://dx.doi.org/10.1007/s10654-021-00758-0
_version_ 1783697975692754944
author Dror, Amiel A.
Daoud, Amani
Morozov, Nicole G.
Layous, Eli
Eisenbach, Netanel
Mizrachi, Matti
Rayan, Doaa
Bader, Ahmad
Francis, Shawky
Kaykov, Edward
Barhoum, Masad
Sela, Eyal
author_facet Dror, Amiel A.
Daoud, Amani
Morozov, Nicole G.
Layous, Eli
Eisenbach, Netanel
Mizrachi, Matti
Rayan, Doaa
Bader, Ahmad
Francis, Shawky
Kaykov, Edward
Barhoum, Masad
Sela, Eyal
author_sort Dror, Amiel A.
collection PubMed
description Vaccine hesitancy is a global health threat which may hinder the widespread acceptance of several COVID-19 vaccines. Following the collection of 2470 responses from an anonymous questionnaire distributed between October and November 2020 across Israel, we analyzed the responses of physicians, life science graduates (biology, virology, chemistry, etc.), and the general public to whether they would obtain a COVID-19 vaccine with particular vaccine characteristics such as vaccine country of origin, technology, side effect profile, efficacy, and other attributes. Physicians and life science graduates were least likely to accept a vaccine based on mRNA technology (30%) while the general population seemed to adopt any vaccine technology if the declared efficacy is above 90% and the country of manufacturing is the USA/UK rather than China or Russia. However, current inoculation rates in Israel far outpace our predicted rate. Our results highlight the importance of tailored vaccine educational campaigns based on population demographic details and specific vaccine concerns.
format Online
Article
Text
id pubmed-8149582
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-81495822021-05-26 Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification Dror, Amiel A. Daoud, Amani Morozov, Nicole G. Layous, Eli Eisenbach, Netanel Mizrachi, Matti Rayan, Doaa Bader, Ahmad Francis, Shawky Kaykov, Edward Barhoum, Masad Sela, Eyal Eur J Epidemiol Covid-19 Vaccine hesitancy is a global health threat which may hinder the widespread acceptance of several COVID-19 vaccines. Following the collection of 2470 responses from an anonymous questionnaire distributed between October and November 2020 across Israel, we analyzed the responses of physicians, life science graduates (biology, virology, chemistry, etc.), and the general public to whether they would obtain a COVID-19 vaccine with particular vaccine characteristics such as vaccine country of origin, technology, side effect profile, efficacy, and other attributes. Physicians and life science graduates were least likely to accept a vaccine based on mRNA technology (30%) while the general population seemed to adopt any vaccine technology if the declared efficacy is above 90% and the country of manufacturing is the USA/UK rather than China or Russia. However, current inoculation rates in Israel far outpace our predicted rate. Our results highlight the importance of tailored vaccine educational campaigns based on population demographic details and specific vaccine concerns. Springer Netherlands 2021-05-26 2021 /pmc/articles/PMC8149582/ /pubmed/34037927 http://dx.doi.org/10.1007/s10654-021-00758-0 Text en © Springer Nature B.V. 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Covid-19
Dror, Amiel A.
Daoud, Amani
Morozov, Nicole G.
Layous, Eli
Eisenbach, Netanel
Mizrachi, Matti
Rayan, Doaa
Bader, Ahmad
Francis, Shawky
Kaykov, Edward
Barhoum, Masad
Sela, Eyal
Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification
title Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification
title_full Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification
title_fullStr Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification
title_full_unstemmed Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification
title_short Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification
title_sort vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149582/
https://www.ncbi.nlm.nih.gov/pubmed/34037927
http://dx.doi.org/10.1007/s10654-021-00758-0
work_keys_str_mv AT droramiela vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification
AT daoudamani vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification
AT morozovnicoleg vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification
AT layouseli vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification
AT eisenbachnetanel vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification
AT mizrachimatti vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification
AT rayandoaa vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification
AT baderahmad vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification
AT francisshawky vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification
AT kaykovedward vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification
AT barhoummasad vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification
AT selaeyal vaccinehesitancyduetovaccinecountryoforiginvaccinetechnologyandcertification